Form 8-K Sarepta Therapeutics, For: Sep 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Sarepta Therapeutics (SRPT) Appoints Edward Kaye as Permanent CEO; Updates on Exec Team
September 21, 2016 8:41 AM EDTSarepta Therapeutics (Nasdaq: SRPT) disclosed the following in a U.S. SEC filing on Wednesday morning:
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On September 20, 2016, the Board of Directors (the Board) of Sarepta Therapeutics, Inc. (the Company) appointed Edward M. Kaye, M.D. as President and Chief Executive Officer (CEO) of the Company and to serve as a member of the Board. Dr. Kaye will continue in his role as Chief Medical Officer, a role which he has held since June 2011. Prior to his new... More
Baird Affirms Sarepta Therapeutics (SRPT) at 'Outperform'; Incrementally Positive on PTAB Decision (BMRN)
September 21, 2016 6:26 AM EDTBaird is incrementally positive on the PTAB ruling for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), which was announced late Tuesday.
Analyst Brian Skorney commented today, Though the dominant story last year was the battle for approval between eteplirsen and BioMarin's (Nasdaq:... More
